CD8A and cancer: Whereas the LTR21B subfamily, enriched both for H3K4me3 in B-cells (FC = 3.59) and for FOXP1 in the HepG2 cancer cell line (FC = 2.70) but not for H3K79me1 in the IMR-90 normal cell line (FC < 1, P-value = 0.85), has been associated with immune checkpoint activity and CD8+ T-cell expression in tumours [25], the LTR10B subfamily, also enriched for H3K4me3 in B-cells (FC = 2.05) and FOXP1 in HepG2 (FC = 2.53) cells but not in IMR-90 cells (FC = 1.01, P-value = 0.45), has been associated with tumour suppressor p53 protein binding along with the MER61 family [26].